Journal of Genetic Disorders & Genetic Reports ISSN: 2327-5790

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Letter to Editor, J Genet Disor Genet Rep Vol: 5 Issue: 1

Anti-Ige (Omalizumab) Improved Trombotic Emboli by Elevating Activated Protein C, Protein S, and Antithrombin III in a Case of Prothrombin G20210A Mutation: Long Term Follow-Up

Arzu Didem Yalcin1* and Betul Celik2
1Department of Internal Medicine, Allergy and Clinical Immunology Unit, Antalya Training and Research Hospital, Antalya 070707, Turkey
2Department of Pathology, Antalya Training and Research Hospital, Antalya 070707, Turkey
Corresponding author : Arzu Didem Yalcin
Department of Internal Medicine, Allergy and Clinical Immunology Unit, Antalya Training and Research Hospital, Antalya 070707, Turkey
E-mail: [email protected]; [email protected]
Received: September 09, 2015 Accepted: December 15, 2015 Published: December 21, 2015
Citation: Arzu Didem Yalcin, Betul Celik (2016) Anti-Ige (Omalizumab) Improved Trombotic Emboli by Elevating Activated Protein C, Protein S, and Antithrombin III in a Case of Prothrombin G20210A Mutation: Long Term Follow-Up. J Genet Disor Genet Rep 5:1. doi: 10.4172/2327-5790.100012

Abstract

Plasma protein C levels were significantly lower compared to patients without acute rejection at the time of rejection, specifically antibody mediated rejection [1,2]. In a parallel mammer Endothelial Protein C Receptor (EPCR) expression was found higher in tubules and arteries of rejection patients than in control patients [3] and activation of the inflammatory/coagulation cascades has been suggested in the pathogenesis of the rejection.

 

Keywords: Protein C; A heterozygous carrier of factor V Leiden and prothrombin G20210A mutation; omalizumab; Anti-IgE; Transplant rejection

Track Your Manuscript

Share This Page

Media Partners

Associations